149 related articles for article (PubMed ID: 33246030)
1. Dysregulated miR-137 and its target EGFR contribute to the progression of pituitary adenomas.
Wei D; Yu Z; Cheng Y; Jiawei H; Jian G; Hua G; Guilan D
Mol Cell Endocrinol; 2021 Jan; 520():111083. PubMed ID: 33246030
[TBL] [Abstract][Full Text] [Related]
2. miR-200b-3p accelerates progression of pituitary adenomas by negatively regulating expression of RECK.
Wang X; Jia Y; Li Q; Yang Q; Liu Y; Wei B; Niu X; Zhang Y; Luo X; Zhao Z; Wang P
Oncol Res; 2024; 32(5):933-941. PubMed ID: 38686051
[TBL] [Abstract][Full Text] [Related]
3. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
[TBL] [Abstract][Full Text] [Related]
4. MicroRNAs expression in pituitary tumors: differences related to functional status, pathological features, and clinical behavior.
Vicchio TM; Aliquò F; Ruggeri RM; Ragonese M; Giuffrida G; Cotta OR; Spagnolo F; Torre ML; Alibrandi A; Asmundo A; Angileri FF; Esposito F; Polito F; Oteri R; Aguennouz MH; Cannavò S; Ferraù F
J Endocrinol Invest; 2020 Jul; 43(7):947-958. PubMed ID: 31939196
[TBL] [Abstract][Full Text] [Related]
5. Next-generation sequencing of microRNAs reveals a unique expression pattern in different types of pituitary adenomas.
He Z; Chen L; Hu X; Tang J; He L; Hu J; Fei F; Wang Q
Endocr J; 2019 Aug; 66(8):709-722. PubMed ID: 31061247
[TBL] [Abstract][Full Text] [Related]
6. AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells.
Ku BM; Bae YH; Koh J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2016 Aug; 34(4):407-15. PubMed ID: 27044261
[TBL] [Abstract][Full Text] [Related]
7. Effect of miR-106b on Invasiveness of Pituitary Adenoma via PTEN-PI3K/AKT.
Zheng Z; Zhang Y; Zhang Z; Yang Y; Song T
Med Sci Monit; 2017 Mar; 23():1277-1285. PubMed ID: 28288092
[TBL] [Abstract][Full Text] [Related]
8. Effects of microRNA-21 targeting PITX2 on proliferation and apoptosis of pituitary tumor cells.
Cui M; Zhang M; Liu HF; Wang JP
Eur Rev Med Pharmacol Sci; 2017 Jul; 21(13):2995-3004. PubMed ID: 28742208
[TBL] [Abstract][Full Text] [Related]
9. DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild-type NSCLC cells to AZD9291.
Li YL; Ding K; Hu X; Wu LW; Zhou DM; Rao MJ; Lin NM; Zhang C
J Cell Mol Med; 2019 Nov; 23(11):7427-7437. PubMed ID: 31454149
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor.
Kim TM; Song A; Kim DW; Kim S; Ahn YO; Keam B; Jeon YK; Lee SH; Chung DH; Heo DS
J Thorac Oncol; 2015 Dec; 10(12):1736-44. PubMed ID: 26473643
[TBL] [Abstract][Full Text] [Related]
11. ADAM12 induces EMT and promotes cell migration, invasion and proliferation in pituitary adenomas via EGFR/ERK signaling pathway.
Wang J; Zhang Z; Li R; Mao F; Sun W; Chen J; Zhang H; Bartsch JW; Shu K; Lei T
Biomed Pharmacother; 2018 Jan; 97():1066-1077. PubMed ID: 29136943
[TBL] [Abstract][Full Text] [Related]
12. Effect of lncRNA HULC knockdown on rat secreting pituitary adenoma GH3 cells.
Rui QH; Ma JB; Liao YF; Dai JH; Cai ZY
Braz J Med Biol Res; 2019; 52(4):e7728. PubMed ID: 30994730
[TBL] [Abstract][Full Text] [Related]
13. Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial-mesenchymal transition phenotype.
Xu J; Zhao X; He D; Wang J; Li W; Liu Y; Ma L; Jiang M; Teng Y; Wang Z; Gu M; Wu J; Wang Y; Yue W; Zhang S
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1413-1422. PubMed ID: 29797219
[TBL] [Abstract][Full Text] [Related]
14. Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.
Eberlein CA; Stetson D; Markovets AA; Al-Kadhimi KJ; Lai Z; Fisher PR; Meador CB; Spitzler P; Ichihara E; Ross SJ; Ahdesmaki MJ; Ahmed A; Ratcliffe LE; O'Brien EL; Barnes CH; Brown H; Smith PD; Dry JR; Beran G; Thress KS; Dougherty B; Pao W; Cross DA
Cancer Res; 2015 Jun; 75(12):2489-500. PubMed ID: 25870145
[TBL] [Abstract][Full Text] [Related]
15. LncRNA MEG8 promotes TNF-α expression by sponging miR-454-3p in bone-invasive pituitary adenomas.
Zhu HB; Li B; Guo J; Miao YZ; Shen YT; Zhang YZ; Zhao P; Li CZ
Aging (Albany NY); 2021 May; 13(10):14342-14354. PubMed ID: 34016788
[TBL] [Abstract][Full Text] [Related]
16. Lineage-dependent role of miR-410-3p as oncomiR in gonadotroph and corticotroph pituitary adenomas or tumor suppressor miR in somatotroph adenomas via MAPK, PTEN/AKT, and STAT3 signaling pathways.
Grzywa TM; Klicka K; Rak B; Mehlich D; Garbicz F; Zieliński G; Maksymowicz M; Sajjad E; Włodarski PK
Endocrine; 2019 Sep; 65(3):646-655. PubMed ID: 31165412
[TBL] [Abstract][Full Text] [Related]
17. AZD9291 Increases Sensitivity to Radiation in PC-9-IR Cells by Delaying DNA Damage Repair after Irradiation and Inducing Apoptosis.
Wu S; Zhu L; Tu L; Chen S; Huang H; Zhang J; Ma S; Zhang S
Radiat Res; 2018 Mar; 189(3):283-291. PubMed ID: 29332537
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effects of Bcl-2 inhibitors with AZD9291 on overcoming the acquired resistance of AZD9291 in H1975 cells.
Liu Z; Gao W
Arch Toxicol; 2020 Sep; 94(9):3125-3136. PubMed ID: 32577785
[TBL] [Abstract][Full Text] [Related]
19. Functions and Mechanisms of Tumor Necrosis Factor-α and Noncoding RNAs in Bone-Invasive Pituitary Adenomas.
Zhu H; Guo J; Shen Y; Dong W; Gao H; Miao Y; Li C; Zhang Y
Clin Cancer Res; 2018 Nov; 24(22):5757-5766. PubMed ID: 29980532
[No Abstract] [Full Text] [Related]
20. Novel Biomarkers for Non-functioning Invasive Pituitary Adenomas were Identified by Using Analysis of microRNAs Expression Profile.
Wu S; Gu Y; Huang Y; Wong TC; Ding H; Liu T; Zhang Y; Zhang X
Biochem Genet; 2017 Jun; 55(3):253-267. PubMed ID: 28315020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
